[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857-209-0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node\u0096targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node\u0096targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node\u0096targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert T. Connelly", "age": 63, "title": "CEO, President & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 678300, "exercisedValue": 0, "unexercisedValue": 239308}, {"maxAge": 1, "name": "Dr. Christopher M. Haqq M.D., Ph.D.", "age": 57, "title": "Executive VP, Head of Research & Development and Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 673821, "exercisedValue": 0, "unexercisedValue": 161616}, {"maxAge": 1, "name": "Prof. Darrell J. Irvine Ph.D.", "title": "Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  DiVecchia", "title": "Senior Vice President of Operations & Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  DeMuth Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan C. Filoon", "title": "General Counsel, Secretary & Compliance Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther  Welkowsky", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joy  Seymour", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thian  Kheoh Ph.D.", "title": "Senior Vice President of Biometrics", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1727481600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 4.87, "open": 5.0, "dayLow": 4.88, "dayHigh": 5.06, "regularMarketPreviousClose": 4.87, "regularMarketOpen": 5.0, "regularMarketDayLow": 4.88, "regularMarketDayHigh": 5.06, "trailingPE": 5.5, "forwardPE": -1.6699669, "volume": 13751, "regularMarketVolume": 13751, "averageVolume": 27009, "averageVolume10days": 21340, "averageDailyVolume10Day": 21340, "marketCap": 54519476, "fiftyTwoWeekLow": 2.96, "fiftyTwoWeekHigh": 11.45, "fiftyDayAverage": 4.4897, "twoHundredDayAverage": 6.02275, "currency": "USD", "enterpriseValue": 57440204, "floatShares": 8430553, "sharesOutstanding": 10774600, "sharesShort": 30029, "sharesShortPriorMonth": 43044, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0028, "heldPercentInsiders": 0.28132, "heldPercentInstitutions": 0.060850002, "shortRatio": 3.25, "shortPercentOfFloat": 0.0034999999, "impliedSharesOutstanding": 10774600, "bookValue": -0.161, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -38665000, "trailingEps": 0.92, "forwardEps": -3.03, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -1.401, "52WeekChange": -0.36591476, "SandP52WeekChange": 0.338071, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ELTX", "underlyingSymbol": "ELTX", "shortName": "Elicio Therapeutics, Inc.", "longName": "Elicio Therapeutics, Inc.", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f5a7063e-a200-3645-afdf-a5955dd38a4c", "messageBoardId": "finmb_214936128", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.06, "targetHighPrice": 10.0, "targetLowPrice": 10.0, "targetMeanPrice": 10.0, "targetMedianPrice": 10.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 3425000, "totalCashPerShare": 0.318, "ebitda": -40998000, "totalDebt": 6419000, "quickRatio": 0.463, "currentRatio": 0.882, "returnOnAssets": -0.96797997, "returnOnEquity": -3.5302398, "freeCashflow": -22082000, "operatingCashflow": -36130000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-30"}]